A citation-based method for searching scientific literature

Su-Jin Kim, Cuilan Nian, Doris J Doudet, Christopher H S McIntosh. Diabetes 2009
Times Cited: 74







List of co-cited articles
859 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
32

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
269
25

Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Irene Hadjiyanni, Laurie L Baggio, Philippe Poussier, Daniel J Drucker. Endocrinology 2008
78
20

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
Nicole A Sherry, Wei Chen, Jake A Kushner, Mariela Glandt, Qizhi Tang, Sue Tsai, Pere Santamaria, Jeffrey A Bluestone, Anne-Marie B Brillantes, Kevan C Herold. Endocrinology 2007
138
20



Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
88
18


Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
264
16


Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
69
15

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
Wilma L Suarez-Pinzon, Robert F Power, Yanhua Yan, Clive Wasserfall, Mark Atkinson, Alex Rabinovitch. Diabetes 2008
131
13

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
James Mu, John Woods, Yun-Ping Zhou, Ranabir Sinha Roy, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Cai Li, Andrew D Howard,[...]. Diabetes 2006
350
13


The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
13

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Carlos E B Couri, Maria C B Oliveira, Ana B P L Stracieri, Daniela A Moraes, Fabiano Pieroni, George M N Barros, Maria Isabel A Madeira, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2009
264
13

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
104
13

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
35
28

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
177
12

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.
Kei Ohnuma, Nam H Dang, Chikao Morimoto. Trends Immunol 2008
160
12

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.
Kalpit A Vora, Gene Porter, Roche Peng, Yan Cui, Kellyann Pryor, George Eiermann, Dennis M Zaller. BMC Immunol 2009
36
25

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
Jun Shirakawa, Hideki Fujii, Kei Ohnuma, Koichiro Sato, Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Megumi Koganei, Hajime Sasaki, Yoji Nagashima,[...]. Diabetes 2011
176
12


Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
59
15

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.
C Klemann, J Schade, R Pabst, S Leitner, J Stiller, S von Hörsten, M Stephan. Clin Exp Immunol 2009
28
28

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
George R Lankas, Barbara Leiting, Ranabir Sinha Roy, George J Eiermann, Maria G Beconi, Tesfaye Biftu, Chi-Chung Chan, Scott Edmondson, William P Feeney, Huaibing He,[...]. Diabetes 2005
389
10

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.
Shuling Yan, Didier Marguet, Jörg Dobers, Werner Reutter, Hua Fan. Eur J Immunol 2003
85
10

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
A Steinbrecher, D Reinhold, L Quigley, A Gado, N Tresser, L Izikson, I Born, J Faust, K Neubert, R Martin,[...]. J Immunol 2001
123
10


A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son,[...]. Diabetes Res Clin Pract 2011
40
20

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
782
9



Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.
D Reinhold, U Bank, F Bühling, U Lendeckel, J Faust, K Neubert, S Ansorge. Immunology 1997
99
9

Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.
J Zhang, Y Tokui, K Yamagata, J Kozawa, K Sayama, H Iwahashi, K Okita, M Miuchi, H Konya, T Hamaguchi,[...]. Diabetologia 2007
55
12

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
607
9

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Aleksey V Matveyenko, Sarah Dry, Heather I Cox, Artemis Moshtaghian, Tatyana Gurlo, Ryan Galasso, Alexandra E Butler, Peter C Butler. Diabetes 2009
182
9

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
9

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
9

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
170
9

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka,[...]. Clin Pharmacol Ther 2005
355
8

GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson,[...]. N Engl J Med 2008
328
8

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Júlio C Voltarelli, Carlos E B Couri, Ana B P L Stracieri, Maria C Oliveira, Daniela A Moraes, Fabiano Pieroni, Marina Coutinho, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2007
351
8

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Norihiko Ogawa, James F List, Joel F Habener, Takashi Maki. Diabetes 2004
127
8

CD26, let it cut or cut it down.
I De Meester, S Korom, J Van Damme, S Scharpé. Immunol Today 1999
379
8

Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
C Durinx, A M Lambeir, E Bosmans, J B Falmagne, R Berghmans, A Haemers, S Scharpé, I De Meester. Eur J Biochem 2000
205
8


(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Dooseop Kim, Liping Wang, Maria Beconi, George J Eiermann, Michael H Fisher, Huaibing He, Gerard J Hickey, Jennifer E Kowalchick, Barbara Leiting, Kathryn Lyons,[...]. J Med Chem 2005
558
8


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.